Answers are grounded in this paper and cite their sources.
Approximately 80% of ovarian cancer cases present with multisite dissemination within the abdominal cavity at diagnosis, a feature strongly linked to dismal prognosis. Yet, whether these disseminated lesions are functionally homogeneous or harbor-distinct metastatic potentials remains unknown—limiting strategies to stratify risk and target metastasis. By integrating single-cell transcriptomics with whole-exome sequencing of matched samples from primary tumors, abdominal implants, and liver metastases in the same patient, we reconstruct the evolutionary trajectory from primary tumor to peritoneal seeding and onward to distant metastasis. We reveal pronounced heterogeneity among abdominal implants: omental tumors frequently retain features of the primary tumor, whereas peritoneal implants adopt transcriptional programs that converge on liver metastases—characterized by enrichment of mesenchymal-like cancer cell states. Mechanistically, ascites-driven inflammation induces mesothelial cells to undergo a fibroblast-like transition, accompanied by elevated secretion of THBS2. These THBS2-enriched, fibroblast-like mesothelial cells act as architects of a peritoneal pre-metastatic niche, facilitating migration and enabling extra-abdominal metastasis as demonstrated by in vitro and mice model. Together, our findings reveal a hierarchical model of ovarian cancer spread and identify THBS2-mediated mesothelial remodeling as a key process enabling systemic metastasis and a promising therapeutic target.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: